NCT02802813View on ClinicalTrials.gov

P.Vivax Treatment Trial

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

June 14, 2016

Primary Completion Date

June 15, 2018

Study Completion Date

June 15, 2018

Conditions
Plasmodium Vivax
Interventions
DRUG

Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ)

DRUG

Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ) placebo

Trial Locations (1)

Unknown

Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Vientiane

All Listed Sponsors
collaborator

Mahidol Oxford Tropical Medicine Research Unit

OTHER

lead

University of Oxford

OTHER

NCT02802813 - P.Vivax Treatment Trial | Biotech Hunter | Biotech Hunter